Comparative ex vivo analysis of Mim8 in thrombin generation assays triggered by activated factor XI or tissue factor
Authors:
- Wan Hui Ong ClausenWCWan Hui Ong Clausen
- Ties LatendorfTLTies Latendorf
- Rielana StehrRSRielana Stehr
- Mirella EzbanMEMirella Ezban
- Jacob LundJLJacob Lund
Open Access
- 10 October 2025
- journal article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (7)
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk (GPP2022)
This publication has 19 references indexed in Scilit:
- FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimeticJournal of Thrombosis and Haemostasis, 2023
- Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adultsResearch and Practice in Thrombosis and Haemostasis, 2023
- In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assaysJournal of Thrombosis and Haemostasis, 2023
- Nonfactor Therapies: New Approaches to Prophylactic Treatment of HaemophiliaHamostaseologie, 2021
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: An international multicentre studyThrombosis Research, 2012
- Thrombin generation: What have we learned?Blood Reviews, 2012
- Remodeling the Blood Coagulation CascadeJournal of Thrombosis and Thrombolysis, 2003
- The epidemiology of inhibitors in haemophilia A: a systematic reviewHaemophilia, 2003
- A Cell-based Model of HemostasisThrombosis and Haemostasis, 2001